AstraZeneca Logs Japan Growth Despite Price Cuts
Strong Pipeline In Its Third-Largest Market
AstraZeneca logs growth in Japan despite a big reimbursement price cut for one of its top sellers and expects 40 approvals in the country over the next six years.
